TC
SCLN

TFS Capital’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

TFS Capital’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-55,104
Closed -$606K – 563
2017
Q2 		$606K Sell
55,104
-40,328
-42% -$403K 0.24% 138
2017
Q1 		$935K Sell
95,432
-49,143
-34% -$491K 0.3% 107
2016
Q4 		$1.56M Buy
144,575
+19,985
+16% +$200K 0.42% 29
2016
Q3 		$1.28M Buy
124,590
+83,572
+204% +$910K 0.31% 115
2016
Q2 		$536K Buy
41,018
+1,580
+4% +$20.7K 0.1% 357
2016
Q1 		$434K Sell
39,438
-199,666
-84% -$1.78M 0.06% 494
2015
Q4 		$2.2M Sell
239,104
-84,311
-26% -$706K 0.24% 144
2015
Q3 		$2.25M Buy
323,415
+84,343
+35% +$722K 0.22% 131
2015
Q2 		$2.35M Buy
239,072
+122,013
+104% +$1.11M 0.23% 114
2015
Q1 		$1.04M Sell
117,059
-20,756
-15% -$165K 0.1% 335
2014
Q4 		$1.21M Sell
137,815
-70,985
-34% -$575K 0.12% 276
2014
Q3 		$1.44M Buy
+208,800
New +$1.25M 0.12% 258
2014
Q1 		– Sell
-42,157
Closed -$212K – 1735
2013
Q4 		$212K Sell
42,157
-203,524
-83% -$979K 0.01% 1267
2013
Q3 		$1.25M Sell
245,681
-324,821
-57% -$1.81M 0.06% 505
2013
Q2 		$2.83M Buy
+570,502
New +$2.71M 0.12% 242

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TFS Capital's SCLN Position: Q3 2017 in Review

TFS Capital sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 55,104 shares — an estimated $606K sold.

TFS Capital first reported a position in SCLN in Q2 2013 and held it in 15 quarters. The position peaked at $2.83M in Q2 2013. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • TFS Capital reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 55,104 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $606K.
  • TFS Capital first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • TFS Capital's Sciclone Pharmaceuticals Inc position peaked at $2.83M in Q2 2013.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.